A Dermatomyositis Patient Developing Chronic Myeloid Leukemia is able Texperience Improvement in the Quality of Daily Life, Following Treatment with Imatinib Mesylate

Case Report

A Dermatomyositis Patient Developing Chronic Myeloid Leukemia is able Texperience Improvement in the Quality of Daily Life, Following Treatment with Imatinib Mesylate

Corresponding authorDr. Kiyomitsu Miyachi, 2-2 Ichibanishinaka-cho, Tsurumi-ku, Yokohama, Kanagawa-ken, 230-0023, Japan, Tel: 81 45 501 5361; Email: mkiyomitsumd_8@hotmail.com


A female patient was originally diagnosed with dermatomyositis in 1985 at the age of 58 because of the presence of interstitial pneumonia and skin lesions. Early in 2008, she experienced a high fever for one week, and essential thrombocytosis was suspected. However, G-banding analysis revealed reciprocal translocation between chromosomes 9 and 22 [t(9;22) (q34;q11.2)] . She was diagnosed with chronic myelogenous leukemia. Daily administration of 400mg of imatinib mesylate was started on April 1, 2008, and the patient’s WBC and thrombocyte counts had dropped from 11,200/μl to 5,500/μl and from 1,491,000/μl to 168,000/μl, respectively, by the end of April. However, imatinib mesylate was reduced to a half dose, because of severe adverse effects such as facial and leg edema in January, 2009. Thereafter, she could walk slowly with a cane, but a compression fracture of her lower lumbar vertebra in April, 2009, rendered her bedridden. We discuss the rare association between dermatomyositis and chronic myelogeneous leukemia and the effect of imatinib mesylate in improving activity of daily life with a mHAQ score of 0.875 in this particular dermatomyositis patient because imatinib mesylate may inhibit interleukin 6 and other cytokine production.

Keywords: dermatomyositis (DM); chronic myeloid leukemia (CML); imatinib mesylate (IM), Interleukin 6 (IL-6); modified Health Assessment Questionnaire (mHAQ); essential thrombocytosis (ET)


Imatinib mesylate (IM) is a computer designed drug which specifically blocks the tyrosine-kinase receptor formed by ABLBCR protein [1]. Previously, we reported that a male rheumatoid arthritis (RA) patient, 75 years old at onset, subsequently developed chronic myelogenous leukemia (CML) at the age of 80. This patient was unique in that his condition became stable not only in relation to CML, but also with regard to rheumatoid arthritis following treatment with IM [2]. Actually, efficacy of IM was also proven in arthritic mice [3,4]. Recently, IM has been shown to be effective not only in treatment for CML but also several manifestations of rheumatic diseases [5]. In the present case, IM treatment was effective not only for CML but also for dermatomyositis (DM).

Case Report

The patient was originally diagnosed with DM in 1985, at the age of 58, because she manifested severe interstitial pneumonia, skin lesions and proximal muscle weakness. She visited the Keigu Clinic when in her most severe condition in September 2003, and tests revealed the presence of anti-nuclear antibody at a 1:80 dilution by indirect immunofluorescence, and anti-Jo1 antibody at a 1:8 dilution by double immunodiffusion. She received 5mg of predonisolone daily for a few years and her modified Health Assessment Questionnaire (mHAQ) score dropped from 2.9 to 1.87. Early in 2008, the patient experienced a high fever for one week, and essential thrombocytosis (ET) was suspected on the basis of an elevated thrombocyte count of 978,000/μl. She was sent to the University Hospital whereupon tests revealed a WBC count of 11,200/μl accompanied by myelocytes at 2.5%, basophiles at 11.5%, and thrombocytes at 1,491,000/μl. The presence of the BCR-ABL1 fusion gene (Philadelphia chromosome, Ph) was confirmed in 59% of segmented and 10% of mononuclear cells by fluorescence in situ hybridization (FISH) [6]. The reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11.2)] was observed in all 20 cells analyzed by G-banding. Daily administration of 400mg of imatinib mesylate (IM) was started on April 1, and the patient’s WBC and thrombocyte counts had dropped to 5,500 and 168,000, respectively, by the end of April. Although the administered dosage of IM was reduced from 400mg to 200mg in January, 2009, because of severe facial and leg edema, she kept in good health (Figure 1a) with an mHAQ of 0.875. Unfortunately, she had difficulty in walking because of a lower vertebral compression fracture which appeared in April, 2011, bringing her mHAQ score up to 2.5. However, she has received IM and continued to be in good health maintaining an active daily life with reduced levels of AST (GOT) and KL-6 for the past 5 years (Figure 1b).

hema table 12.1

Figure 1a. Changes of WBC and Platelet counts before and after treatment of IM mHAQ: modified Health Assessment Questionnare (range 0~3)

hema table 12.1b

Figure 1b. Changes of GOT, KL-6 and Jo-1 levels before and after the treatment of IM
mHAQ: modified Health Assessment Questionnare (range 0~3)


This patient was initially suspected of having ET, but was subsequently diagnosed with CML accompanied by marked thrombocythemia. In particular, CML with marked thrombocythemia, in contrast to ET, is characterized by the presence of smaller megakaryocytes having round hypolobulated nuclei [7]. Plasma cells were also found to be relatively abundant in her bone marrow specimen (Figure 2). Although we have had no opportunity to detect IL-6 levels, it was reported that serum IL-6 levels were higher in CML than myelofibrosis, ET and normal controls [8]. So far, thrombocytosis, persistent fever and abundant plasma cells in her bone marrow suggested to us that IL-6 might be mostly related to the clinical and laboratory manifestations between onset and the early stage of CML in this particular case.

hema fig 12.2

Figure 2. Small megakaryocytes containing small vacuoles in the cytoplasm observed in bone marrow. Plasma cells were thought to be relatively increased as a result of dermatomyositis.

Worldwide, 20 or more patients with connective tissue disease (CTD) associated with CML have been reported (Table 1). Prior to 2002, 11 authors reported 12 cases documenting the association of CTD and CML. Four cases with CTD as a first diagnosis developed CML later, [9-12] however, 6 cases with CML as a first diagnosis developed CTD, mostly following INF therapy [13-18]. IM therapy has been available for the treatment of CML since 2002. Eight cases with first diagnosis of CTD developed CML,2, [19-23] however only 2 CML cases developed CTD, following INF and or Hydroxyurea (HDU) therapy. 20 Probably, regarding CML therapy, IM is more useful and prevalent for CML than INF or HDU. On the other hand, prior to 2002, immune mediated complications occurred in connection with CML, during the treatment with INF or HDU [24].

On the other hand, DM is more closely associated with malignancy including ovarian tumor, lung and gastric cancer than polymyositis [25]. In our particular case, such a malignant disease was not found by CT examination.

hema table 12.2

Table 1. A review literature of association between CTD and CML

Here, we have described a female DM patient 56 years old at the onset of the disease, who subsequently developed CML at age 80. This was an interesting case in that treatment with IM not only put CML in remission, but also appeared to have a positive effect on DM as well. Recent studies on IM have revealed several therapeutic effects owing to its function as a tyrosine kinase inhibitor not only on platelet derived growth factor receptors on the surface of synovial cells in RA, but also on transforming growth factor-β on the skin in systemic sclerosis [26]. Moreover, it was recently reported that IM treatment inhibits IL-6, IL-8, nuclear factor-kuppa B (NF-kB) and activator protein 1 (AP-1) production and modulate intracellular calcium in CML patients, [27] therefore clinically stable manifestations of DM will also be caused by administration of IM.

Conflict of Interest: None


1.Groffen J, Stephnson JR, .Heisterkamp N, de Klein A, Bartram GR et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell .1984,36(1): 93-99.

2.Miyachi K, Ihara A, Hankins RW, Murai S, Maehiro S et al. Efficacy of imatinib mesylate (STI 571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous . Clin Rheumatol. 2003, 22(4-5): 329-332.

3.Koyama K, Hatsushike K, Ando T, Sakuma M, Wako M et al. Imatinib mesylate both prevents and treats the arthritis induced by type Ⅱ collagen antibody in mice. Mod Rheumatol. 2007, 17(4): 306-310.

4.Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K et al. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.  Mod Rheumatol 2011, 21(3): 267-275.

5.Distler JH, Jungel A, Huber LC, Schlze-Horsel U, Schett G et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2006, 56(1): 311-322

6.Takahashi N, Miura I, Saito K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood. 1998, 92(12): 4758-4763.

7.Michiels JJ, Berneman Z, Schroyens W, Kutti J, Swolin B et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol. 2004,83(8): 504-512

8.Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K et al. Serum interleukin (IL)-1,IL-2,slL-2Ra,IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005, 130(5): 709-715.

9.Job-Deslandre C, Menkès CJ, Michalski B, Tessier F. Rheumatoid polyarthritis, Gougerot-Sjögren syndrome and chronic myeloid leukemia. Apropos of 2 cases. Rev Rhum Mal Osteoartic. 1985, 52(4): 247-249.

10.Roumm AD, Medsger TA. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 1985, 28(12): 1336- 1340.

11.Watanabe S, Sugihara T, Takahashi M, Ata K, Kanzaki A et al. Concordant improvement of progressive systemic sclerosis and chronic myelogenous leukemia with interferon-alpha treatment. Rinsho Ketsueki. 1994, 35(9): 895-897

12.Wooten MD, Scott JW, Miller AM, Boh E. Chronic myelogenous leukemia and porphyria cutanea tarda in a patient with limited systemic sclerosis. South Med J. 1998, 91(5): 493-495.

13.Tierney LM Jr, Jensen B, Schwartz RA. Dermatomyositis associated with chronic myelogenous leukemia. Dermatologica. 1985, 171(3): 189-192.

14.Pagliaro LC, Mancias P. Polymyositis associated with chronic myelogenous leukemia Ann Hematol. 1994, 68(4): 213-214.

15.Abe T, Imai K, Tokunoh T, Yawata A, Sasaki S, Hayashi T, Kurokawa S, Matsunaga T, Sakai H, Ishida T. Case report: rheumatoid arthritis complicated by chronic myelogenous leukemia treated with interferon. Nihon Rinsho Meneki Gakkai Kaishi. 1995, 18(1): 70-75.

16.Dubin Kerr L, Troy K, Isola L. Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. J Rheumatol. 1995, 22(12):2356-2358

17.Kötter I, Müller CA, Einsele H, Mohren M, Kanz L. Interferon- alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature. z Rheumatol. 1999, 58(4): 185-195.

18.Minowa R, Miyagawa S, Fukumoto T, Majima T, Shimoyama T et al. Primary Sjögren’s syndrome followed by chronic myelogenous leukemia: a case report with a ten year history. J Dermatol. 1998, 25(7): 460-464.

19.Beretta L, Caronni M, Vanoli M, Scorza R. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol. 2002, 147(2): 385-386.

20.Senel S, Kaya E, Aydogdu I, Erkurt A, Kaku I. Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int. 2006, 26(9): 857-861.

21.Kaşifoğlu T, Korkmaz C, Yaşar S, Gülbaş Z. Scleroderma and chronic myeloid leukemia: a sheer coincidence, a consequence of long lasting D-penicillamine therapy or a plausible relationship of both diseases? Rheumatol Int. 2006, 27(2): 175-177.

22.Ames PR, Aye WW, Beatty C, O’Reilly D. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J Rheumatol. 2008, 35(8): 1682.

23.Nagasaki Y, Miyamoto T, Henzan H, Nagafuji K, Harada M et al. Longstanding remission of adult onset Still’s disease under imatinib therapy in a patient with chronic myelogenous leukemia. J Rheumatol. 2009, 36(6): 1349-1351.

24.Fain O, Gérin M, Bibi-Triki T, Braun T, Fenaux P. [Relapsing polychondritis and chronic myelomonocytic leukemia]. Rev Prat. 2009,59(10): 1350.

25.Tothova E, Kafkova A, Stecova N, Fricova M, Guman T et al. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma. 2002, 49(2): 91-94.

26.Zahr ZA, Baer AN. Malignancy in myositis. Curr RheumatolRep. 2011, 13(3): 208-215.

27.Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology. 2008, 47 Suppl. 5(10-11): 276

28.Ciarcia R, Vitiello MT, Galdierop M, Pacilio C, Iovane V et al. Imatinib treatment inhibit IL-6, IL-8, NF-κB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol. 2012, 227(6): 2798-2803.

Be the first to comment on "A Dermatomyositis Patient Developing Chronic Myeloid Leukemia is able Texperience Improvement in the Quality of Daily Life, Following Treatment with Imatinib Mesylate"

Leave a comment

Your email address will not be published.